We came across a bullish thesis on Verve Therapeutics, Inc. on Stock Region Research’s Substack by Stock Region. In this ...

Verve Therapeutics’ stock was rallying by a record 80% on Eli Lilly’s premium purchase price for the drug-development company.

The first treatment candidate from Verve Therapeutics to begin clinical trials recently produced positive results. Shares of the biotech collapsed despite results that show VERVE-101 can control ...

Detailed price information for Verve Therapeutics Inc (VERV-Q) from The Globe and Mail including charting and trades.

Verve Therapeutics, Inc. (NASDAQ:VERV) is a clinical-stage company focused on revolutionizing the treatment of cardiovascular disease through innovative gene-editing approaches.

Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage company developing a new class of genetic medicines for cardiovascular disease with the potential to transform treatment from chronic ...

Shares of Verve Therapeutics (NASDAQ: VERV) were skyrocketing 75.7% higher as of 10:50 a.m. ET on Tuesday. Eli Lilly (NYSE: LLY) and Verve Therapeutics announced a "definitive agreement for Lilly ...

Verve Therapeutics (VERV) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further ...

Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2024 Financial Results Provided by GlobeNewswire Feb 27, 2025, 12:00:00 PM ...

Why Verve Therapeutics stock tanked There were no issues on the safety front that clearly indicate trouble ahead for VERVE-101 but the initial portion of the study was less than flawless.

Verve Therapeutics (NASDAQ: VERV) stock is seeing explosive gains Tuesday. Yesterday, Verve published promising data from its Heart-2 Phase 1b clinical trial of its VERVE-102 treatment for ...